albireo logo.jpg
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 mai 2021 16h01 HE | Albireo Pharma, Inc.
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
albireo logo.jpg
Albireo Reports Q1 Financial Results and Business Update
06 mai 2021 08h30 HE | Albireo Pharma, Inc.
– BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU– – Completed global commercial agreements for two key top ten markets – – ASSERT & BOLD Phase 3...
albireo logo.jpg
Albireo to Report First Quarter 2021 Financial Results on May 6
29 avr. 2021 08h30 HE | Albireo Pharma, Inc.
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
albireo logo.jpg
Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
13 avr. 2021 08h30 HE | Albireo Pharma, Inc.
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug...
albireo logo.jpg
Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
06 avr. 2021 08h30 HE | Albireo Pharma, Inc.
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in...
albireo logo.jpg
Albireo Announces First Patients Dosed in Two New Studies
25 mars 2021 08h30 HE | Albireo Pharma, Inc.
– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing...
albireo logo.jpg
Albireo Spotlights Global Patient Communities on Rare Disease Day
26 févr. 2021 08h30 HE | Albireo Pharma, Inc.
– Calls to unite global communities affected by rare diseases – – Albireo supports increasing education and advances in research for rare cholestatic liver diseases – BOSTON, Feb. 26, 2021 (GLOBE...
albireo logo.jpg
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
25 févr. 2021 08h00 HE | Albireo Pharma, Inc.
– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch – – Announces odevixibat co-promotion agreement with Travere, a leading rare disease company – – ASSERT global pivotal...
albireo logo.jpg
Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
23 févr. 2021 08h30 HE | Albireo Pharma, Inc.
BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced...
albireo logo.jpg
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
18 févr. 2021 08h30 HE | Albireo Pharma, Inc.
BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...